Apimeds Pharmaceuticals Us, Inc. · AMEX:APUS
Ayrton Capital LLC reported a 9.99% stake in Apimeds Pharmaceuticals Us, Inc. (Schedule 13G)
Event Dec 31, 2025 · Filed Feb 11, 2026
Ayrton Capital LLC reported a 9.99% stake in Apimeds Pharmaceuticals Us, Inc., 1,397,021 shares, as a passive investor on Dec 31, 2025. Filed Feb 11, 2026 (Schedule 13G).
- Stake
- 9.99%
- Shares
- 1,397,021
- Intent
- Passive
- What changed
- Crossed above 5%
- Filed together
- 3 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Ayrton Capital LLC | 9.99% | 1,397,021 |
| Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B | 9.99% | 1,397,021 |
| Waqas Khatri | 9.99% | 1,397,021 |
Source
Related
- Apimeds Pharmaceuticals Us, Inc.
- Ayrton Capital LLC
- Apimeds Pharmaceuticals Us, Inc. shareholders
- Schedule 13D/A · Inscobee Inc. · May 7, 2026
- Schedule 13D/A · Inscobee Inc. · Mar 30, 2026
- Schedule 13D/A · Inscobee Inc. · Mar 20, 2026
- Schedule 13D/A · Inscobee Inc. · Jan 26, 2026
- Schedule 13D · Inscobee Inc. · May 19, 2025